Category: cardiovascular research

Don’t perform heart surgery described in retracted paper, says editor

Screen Shot 2016-02-08 at 10.53.50 PMA journal is retracting a paper about a heart surgery technique after discovering the researchers did not have ethics approval to perform a the procedure on 130 patients. What’s more, the local cardiac surgical society had asked the first author to stop using the method in 2004, six years before the study was complete.

The patients in the study had atrial septal defects — a congenital hole in their hearts that allows blood to leak between chambers. The retraction note concludes with the editor in chief advising other surgeons to not use the method to close the hole described in the retracted article, “Long-term assay of off-pump atrial septal defect closure using vena caval inflow occlusion and minimally invasive approaches in 130 cases.”

A concern from a reader unraveled the paper. The retraction note explains how:

Continue reading Don’t perform heart surgery described in retracted paper, says editor

Paper on alleged – and paradoxical – health benefits of obesity pulled for plagiarism

cancer causes and controlAn article that suggested there is no benefit to being overweight among cancer survivors – the so-called “obesity paradox” – is being retracted for plagiarizing large sections from another paper that explored the same topic in cardiovascular disease.

The journal Cancer Causes & Control pulled the 2014 article last June after determining it contained “large portions” of text from another paper in Preventive Medicine by a different set of authors, which suggested that evidence linking obesity to health benefits in cardiovascular disease may stem from a form of selection bias.

Here’s more from the retraction note: Continue reading Paper on alleged – and paradoxical – health benefits of obesity pulled for plagiarism

8th retraction appears for researcher who faked patient records

S00219150An 8th paper has been retracted for Anna Ahimastos, a heart researcher who faked patient records.

It’s the last in a chain of retractions that were the result of an investigation by her former workplace, Baker IDI Heart & Diabetes Institute in Australia. As with the others, she did not agree to the retraction.

The investigation found fabricated patients records in some papers; in other papers, such as the newly retracted 2010 study in Atherosclerosis, the original data source could not be verified.  The latest retraction — “A role for plasma transforming growth factor-β and matrix metalloproteinases in aortic aneurysm surveillance in Marfan syndrome?” — followed up on a previous clinical trial, examining how a blood pressure drug might help patients with a life-threatening genetic disorder.

That previous trial — which also included 17 patients with Marfan syndrome treated with either placebo or perindopril — has been retracted from JAMA; the New England Journal of Medicine has also retracted a related letter.

The latest retraction note conveys similar information to the other perindopril/Marfan syndrome retractions: Continue reading 8th retraction appears for researcher who faked patient records

Investigation prompts 5th retraction for cancer researcher for “unresolvable concerns”

3.coverAn investigation at the University of New South Wales in Australia has led to a fifth retraction for a cancer researcher long accused of misconduct, due to “unresolvable concerns” with some images.

As we reported in December, UNSW cleared Levon Khachigian of misconduct, concluding that his previous issues stemmed from “genuine error or honest oversight.” Now, Circulation Research is retracting one of his papers after an investigation commissioned by UNSW was unable to find electronic records for two similar images from a 2009 paper, nor records of the images in original lab books.

Again, the retraction note affirms that this is not a sign of misconduct:

UNSW has not attributed any instance of research misconduct or responsibility for the unavailability of the original data to Professor Khachigian or to any of the authors of the publication.

Here’s the retraction note in full for “Angiotensin II-Inducible Smooth Muscle Cell Apoptosis Involves the Angiotensin II Type 2 Receptor, GATA-6 Activation, and FasL-Fas Engagement:” Continue reading Investigation prompts 5th retraction for cancer researcher for “unresolvable concerns”

Investigation of undisclosed conflicts in catheter paper uncovers flawed data, too

cov150hAn investigation into a paper that compared infection rates from different types of central lines started with an allegation about a failure to disclose a conflict of interest, and ended up concluding that the science in the paper was flawed.

The 2013 paper — now retracted by the American Journal of Infection Control — suggested a particular kind of connector between the catheter and the patient could reduce some of the notoriously deadly bloodstream infections associated with the procedure, according to a press release that publicized the work. But last year, the journal issued an expression of concern for the paper, noting there were questions about the data. The retraction note reveals an investigation at Georgia Regents University — now known as Augusta University — started looking into undisclosed conflicts of interest in the paper, and ultimately concluded the science was flawed.

Here’s the retraction note, published in the January 1st 2016 issue of the journal, for “Comparison of central line-associated bloodstream infection rates when changing to a zero fluid displacement intravenous needleless connector in acute care settings”

Continue reading Investigation of undisclosed conflicts in catheter paper uncovers flawed data, too

Eight retractions for fake reviews lead journal to suspend author nominations

home_cover (1)

An investigation has uncovered fake reviews on 21 papers submitted to the Journal of the Renin-Angiotensin Aldosterone System.

After taking a second look at accepted papers with an author-nominated reviewer, the journal discovered that the listed reviewers on the 21 papers, though real people, had never submitted a report.

Eight of the papers have been retracted by JRAAS. The rest had not yet been published, and have now been rejected, explains a commentary by the journal editors. The journal has also stopped allowing authors to nominate reviewers.

The retraction note — the same on all eight papers — explains how the authors “seriously compromised” the review process:

Continue reading Eight retractions for fake reviews lead journal to suspend author nominations

Authors retract antioxidant paper after more work reverses their conclusion

Screen Shot 2015-12-03 at 12.29.58 PM

The authors of a paper about the benefits of an antioxidant found in blueberries known as pterostilbene have retracted it after their subsequent research suggested the antioxidant might actually be harmful.

The paper presented evidence that the antioxidant might help rats after heart attack, in part by inhibiting cell death (apoptosis). But according to the retraction note, more work

found that pterostilbene might induce apoptosis in the heart and can be harmful, and we are now focusing on the phenomenon.

The rest of the retraction note for “Pterostilbene attenuates inflammation in rat heart subjected to ischemia-reperfusion: role of TLR4/NF-κB signaling pathway,” published in the International Journal of Clinical and Experimental Medicine, suggests that the authors would consider republishing their findings if they became more confident in the data:

Continue reading Authors retract antioxidant paper after more work reverses their conclusion

7th retraction for heart researcher who faked patient records

1.coverAnna Ahimastos, a heart researcher who faked patient records, has notched her 7th retraction.

One more paper is expected to be retracted, according to a spokesperson from her former institution, the Baker IDI Heart & Diabetes Institute in Australia.

As with the other retractions, the 2005 paper in Hypertension — about how the hypertension drug ramipril may help alleviate cardiovascular disease — is being pulled after Ahimastos admitted to scientific misconduct. She asserts the data remain valid, and has not signed the retraction notice.

The Hypertension paper has been cited 63 times, according to Thomson Scientific’s Web of Knowledge. Here’s the retraction note in full (the language will be familiar to readers who have been following this case):

Continue reading 7th retraction for heart researcher who faked patient records

My life as a whistleblower: Q&A with Peter Wilmshurst

We’re presenting a Q&A session with Peter Wilmshurst, now a part-time consultant cardiologist who has spent decades embroiled in misconduct investigations as a whistleblower.

Dr-Peter-Wilmshurst-007
Peter Wilmshurst

Retraction Watch: A UK judge recently upheld two findings of dishonesty by the Medical Practitioners Tribunal Service against Andrew Dowson, director of headache services at King’s College Hospital and your former co-investigator. Were you pleased with the verdict? (Last week, Dowson also began a four-month suspension from practicing medicine in the UK.) 

Peter Wilmshurst: In part, because I was pleased that he was shown to be dishonest, because I knew that he was, which was why I reported him. But I wasn’t pleased in the sense that I don’t think the investigation dealt with all the issues involved in the Migraine Intervention with STARflex Technology (MIST) Trial.

RW: What additional issues did you hope to see addressed? Continue reading My life as a whistleblower: Q&A with Peter Wilmshurst

NEJM pulls letter by heart researcher who faked patient records

Screen Shot 2015-11-30 at 10.08.23 AMA heart researcher who fabricated patient records has notched retraction number six — this time, for a letter in the New England Journal of Medicine. She has two more retractions forthcoming.

The retraction comes at the request of Anna Ahimastos’s co-authors, following an investigation into her work by her former workplace, the Baker IDI Heart and Diabetes Institute. The investigation was not able to verify the data referenced in the letter, which includes a citation for a recently retracted JAMA paper.

The retraction note is similar to others for Ahimastos’s papers:

Continue reading NEJM pulls letter by heart researcher who faked patient records